Developments in the inhibition of gastric acid secretion.
Understanding the physiology of gastric acid secretion and the pathophysiology of acid-related diseases (e.g. gastrooesophageal reflux and peptic ulcer) has led to the development of numerous ways to decrease acid exposure. Pharmacologically one can try to neutralize secreted acid by antacids, prevent stimulation of the parietal cell, improve mucosal defences and block the functioning of the proton pump. Proton pump inhibitors (PPIs) inhibit the final step of acid secretion, and are currently the most potent acid inhibitors. Major therapeutic improvement within the PPI class appears unlikely, as agents in this class share similar chemistry, mode of action, and pharmacokinetic profiles. New approaches that block acid secretion are now being developed. Gastrin (CCK2) receptor antagonists and potassium-competitive acid blockers (P-CABs) are in clinical development.
Mössner
J
J
University of Leipzig, Leipzig, Germany. moej@medizin.uni-leipzig.de
Caca
K
K
D000109:Acetylcholine / Q000037:antagonists & inhibitors; D000863:Antacids / Q000627:therapeutic use; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D010295:Parietal Cells, Gastric / Q000502:physiology; D011188:Potassium / Q000378:metabolism; D054328:Proton Pump Inhibitors; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors
D000863:Antacids; D006633:Histamine Antagonists; D054328:Proton Pump Inhibitors; D043887:Receptor, Cholecystokinin B; D000109:Acetylcholine; D011188:Potassium